Eitan Amir

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer
    Eitan Amir
    Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, Canada
    Cancer Treat Rev 36:410-5. 2010
  2. doi Assessing women at high risk of breast cancer: a review of risk assessment models
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G2M9, Canada
    J Natl Cancer Inst 102:680-91. 2010
  3. doi Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Eur J Cancer 48:385-8. 2012
  4. doi Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, The University of Toronto, Toronto, Canada
    Cancer Treat Rev 38:708-14. 2012
  5. doi Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
    Eitan Amir
    Division of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 30:587-92. 2012
  6. doi Defining ovarian failure in amenorrheic young breast cancer patients
    Eitan Amir
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Breast 19:545-8. 2010
  7. doi Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss
    Eitan Amir
    Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada
    Nat Rev Clin Oncol 7:187-8. 2010
  8. doi Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Natl Cancer Inst 103:1299-309. 2011
  9. doi Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer
    Eitan Amir
    Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital Ambulatory Care, Princess Margaret Hospital Toronto General Research Institute, University of Toronto and University Health Network Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Toronto Department of Medical Oncology, R S McLaughlin Durham Regional Cancer Centre, Oshawa Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Am J Clin Oncol 36:436-42. 2013
  10. doi Fulvestrant for advanced breast cancer: a meta-analysis
    Mustafa Al-Mubarak
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Cancer Treat Rev 39:753-8. 2013

Collaborators

Detail Information

Publications37

  1. ncbi Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer
    Eitan Amir
    Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, Canada
    Cancer Treat Rev 36:410-5. 2010
    ..Consequently, clinical testing of lapatinib has been carried out in both HER2-positive and HER2-negative patients. Here we evaluate the clinical efficacy of lapatinib in HER2-positive and HER2-negative patients...
  2. doi Assessing women at high risk of breast cancer: a review of risk assessment models
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G2M9, Canada
    J Natl Cancer Inst 102:680-91. 2010
    ..These steady and incremental improvements in models will need to undergo revalidation...
  3. doi Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Eur J Cancer 48:385-8. 2012
    ..Composite measures comprising patient reported outcomes and intermediate endpoints such as PFS may be the solution and should be investigated further...
  4. doi Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, The University of Toronto, Toronto, Canada
    Cancer Treat Rev 38:708-14. 2012
    ..Retrospective studies suggest that discordance between receptor expression of primary and recurrent breast cancer exists...
  5. doi Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
    Eitan Amir
    Division of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 30:587-92. 2012
    ..This prospective study investigated receptor status of primary tumors and metastases in the same patient and assessed the impact of discordance on patient management and survival...
  6. doi Defining ovarian failure in amenorrheic young breast cancer patients
    Eitan Amir
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Breast 19:545-8. 2010
    ..It is hoped that the development of novel surrogates may allow clinicians to more accurately assess menopausal status and thereby facilitate tailored and individualised therapy for this common group of patients...
  7. doi Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss
    Eitan Amir
    Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada
    Nat Rev Clin Oncol 7:187-8. 2010
    ....
  8. doi Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Natl Cancer Inst 103:1299-309. 2011
    ..We conducted a literature-based meta-analysis of randomized trials to examine whether the relative toxicity of aromatase inhibitors compared with tamoxifen may explain this finding...
  9. doi Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer
    Eitan Amir
    Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital Ambulatory Care, Princess Margaret Hospital Toronto General Research Institute, University of Toronto and University Health Network Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Toronto Department of Medical Oncology, R S McLaughlin Durham Regional Cancer Centre, Oshawa Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Am J Clin Oncol 36:436-42. 2013
    ..This study assessed the feasibility of conducting a randomized trial of less frequent bisphosphonate administration in women with breast cancer and low-risk bone metastases...
  10. doi Fulvestrant for advanced breast cancer: a meta-analysis
    Mustafa Al-Mubarak
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Cancer Treat Rev 39:753-8. 2013
    ..Trials of fulvestrant are limited by inconsistent study populations and drug dosing. The optimal use of fulvestrant in advanced breast cancer is therefore unclear...
  11. doi The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs
    Saroj Niraula
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 30:3012-9. 2012
    ..There is relatively less emphasis on toxicity. In our study, we analyze serious toxicities of newly approved anticancer drugs reported in pivotal RCTs used for drug registration...
  12. doi A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases
    Eitan Amir
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 116:284-91. 2010
    ..This study therefore aimed to assess the effect of this dose of vitamin D(3) in patients with bone metastases from breast cancer...
  13. doi Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions
    Alberto Ocana
    Drug Development Program, Princess Margaret Hospital, Toronto, Canada M5G 2M9
    Cancer Treat Rev 35:685-91. 2009
    ..This review will describe the biologic rationale that justifies the development of these agents in breast cancer focusing on the current status and future directions...
  14. ncbi Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
    Francisco E Vera-Badillo
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Breast Cancer Res Treat 146:235-44. 2014
    ..Further validation of the independent prognostic impact of multifocality is warranted. ..
  15. doi Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 29:2543-9. 2011
    ..The relationship between market pricing of new anticancer drugs and the magnitude of clinical benefit caused by them has not been reported...
  16. ncbi Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients
    Orit Freedman
    Division of Medical Oncology, Princess Margaret Hospital, Suite 5 205, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Breast Cancer Res Treat 118:377-83. 2009
    ..70 (95% CI 0.60-0.80). This model was able to identify risk information that could be helpful in assessing which patients would most likely benefit from fulvestrant as an intervention with the objective being a delay in chemotherapy...
  17. pmc Extended adjuvant tamoxifen for early breast cancer: a meta-analysis
    Mustafa Al-Mubarak
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and Department of Medicine, University of Toronto, Toronto, Canada Ministry of Higher Education, Riyadh, Saudi Arabia
    PLoS ONE 9:e88238. 2014
    ..Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear...
  18. doi The evolving landscape of protein kinases in breast cancer: clinical implications
    Alberto Ocana
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
    Cancer Treat Rev 39:68-76. 2013
    ..In addition, we will evaluate the clinical development of kinase inhibitors to identify areas of knowledge that could be explored in future preclinical and clinical studies...
  19. doi Benefits and harms of detecting clinically occult breast cancer
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave 5 124, Toronto, ON M5G 2M9, Canada
    J Natl Cancer Inst 104:1542-7. 2012
    ....
  20. doi Targeting DNA repair in breast cancer: a clinical and translational update
    Eitan Amir
    Medical Oncology Department, Princess Margaret Hospital, 610 University Avenue, Toronto, Canada
    Cancer Treat Rev 36:557-65. 2010
    ..In this review we will update the clinical and biological data underlying the development of drugs targeting DNA repair with a focus on breast cancer...
  21. doi Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
    Bostjan Seruga
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Breast Cancer Res Treat 122:609-17. 2010
    ..There are limited data supporting the association of potent inhibitors of CYP2D6 and detrimental outcome, but avoidance of such drugs seems reasonable...
  22. doi Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials
    Arif Manji
    Arif Manji, Irene Brana, Eitan Amir, Ian F Tannock, Philippe L Bedard, Amit Oza, Lillian L Siu, and Albiruni R Abdul Razak, Princess Margaret Cancer Centre, University Health Network George Tomlinson, University of Toronto and Arif Manji, Hospital for Sick Children, Toronto, and Southlake Regional Health Centre, Newmarket, Ontario, Canada
    J Clin Oncol 31:4260-7. 2013
    ..To evaluate the use and objectives of expansion cohorts in phase I cancer trials and to explore trial characteristics associated with their use...
  23. doi Phase III trials of targeted anticancer therapies: redesigning the concept
    Alberto Ocana
    Authors Affiliation Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada
    Clin Cancer Res 19:4931-40. 2013
    ..Here, we review these problems and suggest that phase III trials with adaptive designs in selected prescreened populations could reduce these limitations...
  24. doi Management of small HER2 overexpressing tumours
    Arnoud Templeton
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Department of Medicine, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Breast Cancer Res Treat 136:289-93. 2012
    ....
  25. doi Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials
    Orit Freedman
    Department of Medicine, University of Toronto, Toronto, Canada
    Support Care Cancer 19:315-22. 2011
    ..This study determined the prevalence and quality of reporting of supportive care treatment for common chemotherapy-induced toxicities in phase III, breast cancer chemotherapy trials...
  26. ncbi Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis
    Ivan Diaz-Padilla
    Division of Medical Oncology, Centro Integral Oncologico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada Electronic address
    Crit Rev Oncol Hematol 88:154-67. 2013
    ..The association between the deficiency in mismatch repair (MMR) genes and prognosis in women with endometrial cancer is unclear. Here we report a systematic review and meta-analysis exploring this association...
  27. doi Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Anne M Horgan
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada Department of Medical Oncology, Waterford Regional Hospital, Waterford, Ireland Electronic address
    J Geriatr Oncol 5:119-26. 2014
    ..Prostate cancer is a disease of older men. Weekly docetaxel (DPq1w) is often favored over the standard three-weekly regimen (DPq3w) due to concerns about safety and tolerability in this population...
  28. doi Benefit and harms of new anti-cancer drugs
    Francisco E Vera-Badillo
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and the Department of Medicine, University of Toronto, 610 University Avenue, Toronto, ON, Canada
    Curr Oncol Rep 15:270-5. 2013
    ..In some cases, the small improvement in survival has come at a cost of substantial excess toxicity, leading some to consider such therapy as having equipoise...
  29. doi p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis
    Steven Habbous
    Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada
    Clin Cancer Res 18:6407-15. 2012
    ..There were no associations of this variant with overall risk or initiation of cancer in either HPV-positive or HPV-negative patients. Clin Cancer Res; 18(23); 6407-15...
  30. pmc 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    Breast Cancer Res Treat 133:1077-88. 2012
    ..34). In this high risk population, higher BMI was associated with a greater breast cancer risk. Serum levels of 25OHD, insulin, CRP, and leptin were not independent predictors of either breast cancer risk or tamoxifen benefit...
  31. doi Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
    Orit C Freedman
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Crit Rev Oncol Hematol 72:56-64. 2009
    ..Many of these trials will be reported in the near future. In this article we review possible subgroups that may benefit from adjuvant treatment with BPs, and ongoing trials that may offer more definitive answers...
  32. doi Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer
    Oliver Teuffel
    Division of Haematology Oncology, Hospital for Sick Children, Toronto, Ontario, Canada
    Pediatrics 127:e279-86. 2011
    ..Clinical data suggest, however, that outpatient management might be a safe and efficacious alternative for patients with low-risk FN episodes...
  33. doi Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review
    Ivan Diaz-Padilla
    Division of Medical Oncology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Gynecol Oncol 124:354-65. 2012
    ..A systematic review for all eligible polymorphisms has not yet been reported. The aim of this study was to summarize the current status of the field and provide direction for future research...
  34. doi Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, ON, Canada
    Drugs 71:1527-36. 2011
    ..We also highlight issues of ongoing debate amongst key stakeholders and examine some of the commercial challenges faced by developers of biosimilars. As the leader of biosimilars drug approval and product uptake, the EU is highlighted...
  35. pmc A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
    Christina L Addison
    Division of Medical Oncology, Ottawa Hospital Cancer Centre, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
    Breast Cancer Res Treat 144:615-24. 2014
    ..Larger trials are required to assess the roles of biomarkers as predictors of adequacy of de-escalated therapy...
  36. doi Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis
    Anne M Horgan
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 30:1934-40. 2012
    ..The benefit of adjuvant therapy (AT) for biliary tract cancer (BTC) is unclear, with conflicting results from nonrandomized studies. We report a systematic review and meta-analysis to determine the impact of AT on survival...
  37. doi Pharmacogenetic and germline prognostic markers of lung cancer
    Anne M Horgan
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Thorac Oncol 6:296-304. 2011
    ..We evaluated the overall contribution of candidate polymorphism association studies to our current understanding of the genetic predictors of lung cancer outcomes...